Le Lézard
Classified in: Health
Subjects: CCA, PET

Aratana Therapeutics to Report Second Quarter 2018 Financial Results


LEAWOOD, Kan., July 10, 2018 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, will host a live conference call on Friday, August 3, 2018 at 8:30 a.m. ET to discuss financial results from the second quarter ended June 30, 2018.

Aratana Therapeutics logo

Interested participants and investors may access the audio webcast or use the conference call dial-in:

1 (866) 364-3820 (U.S.)
1 (855) 669-9657 (Canada)
1 (412) 902-4210 (International)

A replay of the second quarter 2018 results teleconference will be available the same day of the event by approximately 11 a.m. ET and an audio webcast will be accessible for 90 days in the Aratana Investor Room. For a replay of the call, use the below dial-in and conference ID 10122186:

1 (877) 344-7529 (U.S.)
1 (855) 669-9658 (Canada)
1 (412) 317-0088 (International)

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. As a pioneer in pet therapeutics, Aratana's mission is to deliver safe and effective therapeutics that elevate the standard of care in veterinary medicine. We work with companion animal veterinarians to bring new therapeutics to market that support the needs of pets and their owners. For more information, please visit www.aratana.com.

Contacts
For investor inquires:
Craig Tooman
[email protected]
(913) 353-1026

For media inquiries:
Rachel Reiff
[email protected]
(913) 353-1050

SOURCE Aratana Therapeutics


These press releases may also interest you

at 02:05
Antech, the veterinary diagnostics company focused on partnering with veterinary professionals to predict, diagnose, and monitor wellness and disease, today announced the launch of the breakthrough in-hospital Nu.Q® Canine Cancer Test in Europe. A...

at 02:00
Red Arrow Therapeutics Inc. closed a $4.5M Seed Extension round, raising from four, top-tier institutional investors in Japan. Participants of this round are: Beyond Next Ventures Inc.The University of Tokyo Edge Capital Partners Co., Ltd.Keio...

at 01:05
Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care...

at 01:01
Allied Market Research published a report, titled, "Electroceuticals/Bioelectric Medicine Market by Product (Cardiac Pacemakers and Implantable Cardioverter Defibrillators, Cochlear Implants, Spinal Cord Stimulators, Deep Brain Stimulators, Vagus...

at 00:49
Allied Market Research published a report, titled, "Inhaled Nitric Oxide Market by Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease, Acute Respiratory Distress Syndrome, and Others): Global Opportunity Analysis and...

at 00:45
Vertex Pharmaceuticals Incorporated and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production...



News published on and distributed by: